Ifinatamab deruxtecan - Daiichi Sankyo Company
Alternative Names: DS-7300; DS-7300a; I-DXd; MK-2400Latest Information Update: 30 May 2025
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co
- Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Prostate cancer; Small cell lung cancer; Squamous cell cancer
- Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Phase I/II Solid tumours
Most Recent Events
- 19 May 2025 Ifinatamab deruxtecan - Daiichi Sankyo Company receives Orphan Drug status for Small cell lung cancer in Japan
- 19 May 2025 Ifinatamab deruxtecan - Daiichi Sankyo Company receives Orphan Drug status for Small cell lung cancer in Taiwan
- 13 May 2025 Phase-III clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater, Metastatic disease) in Taiwan, Israel, South Korea, USA (IV) (NCT06925737)(EudraCT2024-517423-40-00)